Risk Factors for Survival from Neuroendocrine Neoplasia with Unknown Primary Tumor Site Abstract #1237

Introduction: Neuroendocrine neoplasia (NEN) with unknown primary site (NEN-CUP) may have a poor prognosis. We evaluated the clinical presentation, therapy, outcome, and risk factors for adverse outcomes in patients with NEN-CUP.
Aim(s): Role of surgery in NEN-CUP
Materials and methods: In 243 patients who had NEN, a retrospective review was performed in 38 patients who had NEN-CUP tumors. The 38 patients who had NEN-CUP were evaluated in 3 groups: group 1 (surgery; primary tumor detected; n=10); group 2 (surgery; no primary tumor detected; n=10); and group 3 (no surgery; n=18). Risk factors were evaluated with univariate and multivariate analysis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: Dr. Nehara Begum

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases
Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Authors: Partelli S, Inama M, Rinke A, Begum N, ...
#1746 Clinical Outcomes in Small Neuroendocrine Tumours Treated with Intestinal Surgery in Tertiary Centre
Introduction: Patients with Small Bowel Neuroendocrine Tumours (SBNET) may require small bowel surgery either as an emergency or electively.Robust data from Tertiary Referral Centres (TRC) are lacking.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Georgios Demetriou
#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors: Pape U F, Bacher M, Fottner C, Lahner H, ...
Keywords: everolimus, outcome
#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register
Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Keywords: sunitinib, outcome
#326 Long-term Survival and Quality of Life in Patients with Ileum NET: A Single Center Experience
Introduction: Neuroendocrine tumors of the small bowel can be differentiated in terms of progression, survival time and health-related quality of life from endothelial tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anne Reincke
Authors: Reincke A, Zahn S, Hornung H, Jauch K W, ...